Elbeik   Associates, LLC

PUBLICATIONS: TAREK ELBEIK, Ph.D.

Peer Reviewed Publications:



 1. Shults K, Flye-Blakemore L, Patterson BK, Elbeik T. Analysis of multiple cell reservoirs expressing unspliced HIV-1 gag-pol mRNA in patients on antiretroviral therapy. Future Virology. 2012;7(8): 819-832.

 2. Elbeik T. Shults K, Patterson BK. Simultaneous Ultrasensitive Subpopulation Staining/Hybridization In Situ: Multiplex Analyses of Transcriptionally Active HIV-1 Intact Cell Reservoirs. Future Virology. 2012;7(8):741-744. Editorial

 3. Cherepakhina NE, Shogenov ZS, Elbeik T, Akhmedilova KA, Agirov MM, Tabaksoeva ZhA, Ogneva EA, Matsuura E, Mukhin NA, Shoenfeld Y, Pal'tsev MA, Suchkov SV. Post-infectious clinical-immunological syndrome and its place in clinical practice. [Article in Russian] Ter Arkh. 2009;81(12):71-8.

 4. Shogenov ZS, Kekenadze NN, Vorob'eva SE, Usik MP, Elbeik T, Akhmedilova KA, Mamonova EE, Matsuura E, Pal'tsev MA, Suchkov SV.  Architectonics of cell subpopulations of peripheral blood in patients with autoimmune myocarditis: clinical and pathogenetic aspects [Article in Russian] Ter Arkh. 2008;80(12):23-8.

 5. Lan YC*, Elbeik T*, Dileanis J, Ng V, Chen YJ, Leu HS, Cheng SH, Wong JC, Wong WW, Chen YM.  Molecular epidemiology of HIV-1 subtypes and drug resistant strains in Taiwan. J Med Virol. 2008 Feb;80(2):183-191. * Lan and Elbeik share first authorship

 6. Elbeik T, Dalessandro R, Loftus RA, Beringer S. HIV-1 and HCV viral load cost models for bDNA: 440 Molecular System versus real-time PCR AmpliPrep/TaqMan test. Expert Rev Mol Diagn. 2007 Nov;7(6):723-753

 7. Elbeik T, Dalessandro R, Loftus RA, Beringer S. HIV-1 and HCV viral load cost models for bDNA: 440 Molecular System versus real-time PCR AmpliPrep/TaqMan test. Expert Rev Mol Diagn. 2007 Nov;7(6):723-753

 8. Elbeik T, Loftus RA, Beringer S. Cost assessment of the automated VERSANT 440 Molecular System versus the semi-automated System 340 bDNA Analyzer platforms. Expert Rev Mol Diagn. 2007 Nov;7(6):713-722

 9. Suchkov SV, Petrunin DD, Kostalevskaya AV, Kachkov IA, Elbeik T, Matsuura E, Paltsev MA. Cancer-associated immune-mediated syndromes: Pathogenic values and clinical implementation. Biomed Pharmacother. 2007 Jul;61(6):323-37

 10. Mazo EB, Vinnitsky LI, Litvinov VA, Cherepakhina NE, Burdakova YA, Elbeik T, Mukhin NA, Paltsev MA, Suchkov SV. Chronic pyelonephritis: immunopathogenesis and clinicodiagnostic value of its specific features. [Article in Russian]. Ter Arkh. 2007;79(1):85-89. Russian.

 11. Elbeik T, Nassos P, Kipnis P, Haller B, Ng V.L.  Evaluation of the VACUTAINER PPT Plasma Preparation Tube for Use with the Bayer VERSANT Assay for Quantification of Human Immunodeficiency Virus Type 1.  Journal of Clinical Microbiology. August 2005. 43(8): 3769-3771

 12. Roland ME, Elbeik TA, Kahn JO, Bamberger JD, Coates TJ, Krone MR, Katz MH, Busch MP, Martin JN.  HIV RNA Testing in the Context of Nonoccupational Postexposure Prophylaxis.  Journal of Infectious Diseases.  August 2004. 190(3): 598-604

 13. Elbeik T, Markowitz N, Nassos P, Kumar U, Beringer S, Haller B and Ng V.  Simultaneous Run of the Bayer VERSANT HIV-1 Version 3.0 and HCV bDNA Version 3.0 Quantitative Assays on the System 340: Reliable Quantitation with Improved Work Flow.  Journal of Clinical Microbiology, July 2004. 42(7): 3120-3127

 14. Cuchkov SV, Moskalets OV, Cherepakhina NE, Burdakova IA, Suntsova IG, Shumskii VI, Shaikhaev GO, Elbeik T, Beringer S, Petrauskene O.  Modern methods immunological and genetical diagnostics in clinical practice.  [Article in Russian]   Terapevticheskii Arkhiv, April 2004. 76(4): 78-83

 15. Elbeik T, Surtihadi J, Destree M, Gorlin J, Holodniy M, Jortani SA, Kuromoto K, Ng V, Valdes R Jr., Valsamakis A, Terrault NA.  Multicenter Evaluation of the Performance Characteristics of the Bayer VERSANT HCV RNA 3.0 Assay (bDNA).  Journal of Clinical Microbiology, February 2004. 42(2): 563-569

 16. Abrams D, Leiser R, Hilton J, Shade S, Elbeik T, Aweeka F, Benowitz N, Bredt B, McCune J, Mitchell T, Mulligan K, Schambelan M.  Short-term effects of cannabinoids in patients with human immunodeficiency virus-1 infection. Annals of Internal Medicine, August 2003. 139(4): 258-266

 17. Elbeik T, Delassandro R, Chen YMA, Soutchkov SV, Loftus RA, Beringer S.  Global Cost Modeling Analysis of HIV-1 and HCV viral load assays: A comparative cost analysis of Bayer VERSANT® assay, Roche AMPLICOR MONITOR® test and COBAS AMPLCOR MONITOR® test. Expert Review of Pharmacoeconomics and Outcomes Research, August 2003. 3(4): 383-407

 18. Gleaves C, Welle J, Campbell M, Elbeik T, Ng V, Taylor P, Kuramoto K, Aceituno S, Lewalski E, Joppa B, Sawyer L, Schaper C, McNairn D, Quinn T.  Multicenter evaluation of the Bayer VERSANT HIV-1 RNA 3.0 assay: analytical and clinical performance. Journal of Clinical Virology. August 2002. 25 (2): 205-216

 19. Elbeik T, Loftus RA, Beringer S.  Health care industries’ perspective of viral load assays: the VERSANT HIV-1 RNA 3.0 assay. Expert Review of Molecular Diagnostics, May 2002. 2 (3): 275-285

 20. Elbeik T, Alvord WG, Trichavaroj R, de Souza M, Dewar R, Brown A, Chernoff D, Michael NL, Nassos P, Hadley K, Ng V.  Comparative Analysis of HIV-1 Viral Load Assays on Subtype Quantification: Bayer Versant HIV-1 RNA 3.0 Versus Roche Amplicor HIV-1 Monitor Version 1.5. Journal of Acquired Immune Deficiency Syndromes, April 2002. 29 (4): 330-339

 21. ElbeikT, Hoo B, Campodonico M, Dileanis J, Fay F, Bortolozzi R, Benetti S, Fay O, Marlowe N, Petrauskene O, Chernoff D, Smith L, Ng V. The In-Vivo Emergence of Drug Resistance Mutations at Less Than 50 HIV-1 RNA Copies/ml That Are Maintained at Viral Rebound in Longitudinal Plasma Samples From Human Immunodeficiency Virus Type-1 Infected Patients on Highly Active Antiretroviral Therapy. Journal of Human Virology, December 2001. 4: 317-328

 22. Elbeik T, Charlebois E, Nassos P, Kahn J, Hecht FM, Yajko D, Ng V, Hadley WK.  Quantitative and Cost Comparison of Ultrasensitive HIV-1 RNA Viral Load Assays: Bayer bDNA Quantiplex versions 3.0 and 2.0 and Roche PCR Amplicor Monitor version 1.5. Journal of Clinical Microbiology. March 2000. 38 (3): 1113-1120

 23. Locher CP, Grant RM, Collisson EA, Reyes-Terán G, Elbeik T, Kahn JO, Levy JA. Antibody and cellular immune responses in breakthrough infection subjects after HIV type 1 glycoprotein 120 vaccination.  Aids Research and Human Retroviruses, December 1999. 15(18): 1685-923

 24. Haslett PA, Klausner JD, Makonkawkeyoon S, Moreira A, Metatratip P, Boyle B, Kunachiwa W, Maneekarn N, Vongchan P, Corral LG, Elbeik T, Shen Z, Kaplan G.  Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients. Aids Research and Human Retroviruses, September 1999. 15(13): 1169-79

 25. Deeks SG, Hecht FM, Swanson M, Elbeik T, Loftus R, Cohen PT, Grant RM. Virologic outcomes with protease inhibitor therapy in an urban AIDS clinic: Relationship between baseline characteristics and response to both initial and salvage therapy. AIDS, 1999. 13: F35-F44

 26. Liegler TJ, Yonemoto W, Elbeik T, Vittinghoff E, Buchbinder SP, Greene WC.  Diminished spontaneous apoptosis in lymphocytes from human immunodeficiency virus-infected long-term nonprogressors. Journal of Infectious Diseases, September 1998. 178(3): 669-679

 27. Fiscus SA, Hughes MD, Lathey JL, Jackson JB, Rasheed S, Elbeik T, Reichman R, Japour A, Byington R, Scott W, Griffith BP, Katzenstein DA, Hammer SM.  Changes in virologic markers as predictors of CD4 cell decline and progression of disease in human immunodeficiency virus type-1 infected adults treated with nucleosides.  Journal of Infectious Diseases, March 1998. 177(3): 625-633

 28. Lathey JL, Hughes MD, Fiscus SA, Pi T, Jackson JB, Rasheed S, Elbeik T, Reichman R, Japour A, D'Aquila RT, Scott W, Griffith BP, Hammer SM, Katzenstein DA.  Variability and prognostic values of virologic and CD4 cell measures in human immunodeficiency virus type 1-infected patients with 200-500 CD4 cells/mm(3) (ACTG 175). Journal of Infectious Diseases, March 1998. 177(3): 617-624

 29. Hughes MD, Johnson VA, Hirsch MS, Bremer W, Elbeik T, Erice A, Kuritzkes DR, Scott WA, Spector SA, Basgoz N, Fischl MA, D'Aquila RT.  Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response.  Annals of Internal Medicine, June 1997. 126 (12): 929-938

 30. Hartley CA, Gilbert MJ, Brigido L, Elbeik T, Levy JA, Crowe SM, Mills J.  Human immunodeficiency virus grown in CD4-expressing cells is associated with CD4.  Journal of General Virology, 1996; 77: 2015-2023

 31. Katzenstein D, Hammer S, Hughes M, Gundacker H, Jackson B, Fiscus S, Rasheed S, Elbeik T, Reichman R, Japour A, Merigan T, Hirsch M.  The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter.  New England Journal of Medicine, October 1996. 335 (15): 1091-1098

 32. Harrer T, Harrer E, Kalams SA, Elbeik T, Staprans SI, Feinberg MB, Cao Y, Ho DD, Yilma T, Caliendo AM, Buchbinder SP, Walker BD.   Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection. Aids Research and Human Retroviruses, May 1996. 12(7): 585-592

 33. Harrer T, Harrer E, Kalams SA, Barbosa P, Trocha A, Johnson RP, Elbeik T, Feinberg MB, Buchbinder SP, Walker BD. Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. Breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load.  Journal of Immunology, April 1996. 156(7): 2616-2623

 34. Levy JA, Ramachandran B, Barker E, Guthrie J, Elbeik T.  Plasma viral load, CD4+ cell counts, and HIV-1 production by cells.  Science, February 1996. 271(5249): 670-671

 35. Staprans SI, Hamilton BL, Follansbee SE, Elbeik T, Barbosa P, Grant RM, Feinberg MB. Activation of virus replication after vaccination of HIV-1-infected individuals.  Journal of Experimental Medicine, December 1995. 182(6): 1727-1737

 36. Kahn JO, Steimer KS, Baenziger J, Duliege AM, Feinberg M, Elbeik T, Chesney M, Murcar N, Chernoff D, Sinangil F.  Clinical, immunologic, and virologic observations related to human immunodeficiency virus (HIV) type 1 infection in a volunteer in an HIV-1 vaccine clinical trial.  Journal of Infectious Diseases, May 1995. 171(5): 1343-1347

 37. Lathey JL, Fiscus SA, Rasheed S, Kappes JC, Griffith BP, Elbeik T, Spector SA, Reichelderfer PS. Optimization of quantitative culture assay for human immunodeficiency virus from plasma. Plasma Viremia Group Laboratories of the AIDS Clinical Trials Group (National Institute of Allergy and Infectious Diseases). Journal of Clinical Microbiology, December 1994. 32(12): 3064-3067

 38. Safrin S, Elbeik T, Phan L, Robinson D, Rush J, Elbaggari A, Mills J. Correlation between response to acyclovir and foscarnet therapy and in vitro susceptibility result for isolates of herpes simplex virus from human immunodeficiency virus-infected patients. Antimicrobial Agents and Chemotherapy, June 1994. 38(6): 1246-1250

 39. Safrin S, Elbeik T, Mills J. A rapid screen test for in vitro susceptibility of clinical herpes simplex virus isolates.  Journal of Infectious Diseases, April 1994. 169(4): 879-882

 40. Crowe SM, Mills J, Elbeik T, Lifson JD, Kosek J, Marshall JA, Engleman EG, McGrath MS.  Human immunodeficiency virus-infected monocyte-derived macrophages express surface gp120 and fuse with CD4 lymphoid cells in vitro: a possible mechanism of T lymphocyte depletion in vivo. Clinical Immunology and Immunopathology, November 1992. 65(2): 143-151

 41. Crowe S, Elbeik T, Ulrich P, Mills J, Moss A.  No Evidence of Occult Human Immunodeficiency Virus in Seronegative Individuals at Very High Risk of Infection. Journal of Medical Virology, 1991; 35: 160-164

 42. Crowe S, McGrath M, Elbeik T, Kirihara J, Mills J.  Comparative Assessment of Antiretrovirals in Human monocyte-Macrophages and Lymphoid Cell Lines Infected with the Human Immunodeficiency Virus. Journal of Medical Virology, 1989; 29: 176-180

 43. Ulrich PP, Busch MP, Elbeik T, Shiota J, Vennari J, Shriver K, Vyas GN.  Assessment of Human Immunodeficiency Virus Expression in Co-cultures of Peripheral Blood Mononuclear Cells from Healthy Seropositive Subjects. Journal of Medical Virology, 1988; 25: 1-10

 44. Elbeik T, Razzaque A, Jariwalla R, Cihlar R, Rosenthal LJ.  Multiple Transforming Regions of Human Cytomegalovirus DNA. Journal of Virology, 1986; 60: 645-652

Peer Reviewed Books:

 1. T. Elbeik, T.W. Chun, H. Imamichi, T. Imamichi, V. Natarajan, D. Waters, R.L. Dewar, and H. Highbarger.  Quantitation of viremia and determination of drug resistance in patients with human immunodeficiency virus infection. In: Manual of Clinical Laboratory Immunology Seventh Edition. 2005

 2. T. Elbeik, T.W. Chun, H. Imamichi, T. Imamichi, V. Natarajan, D. Waters, R.L. Dewar, and H. Highbarger.  Quantitation of viremia and determination of drug resistance in patients with human immunodeficiency virus infection. In: Manual of Clinical Laboratory Immunology Sixth Edition. Editors: Rose, NR, Hamilton, RG, and Detrick, B. Publisher: American Society for Microbiology. 2002. pp. 772-789

 3. T. Elbeik, R.L. Dewar, V. Natarajan.  Isolation and detection of human immunodeficiency virus.  In:  Manual of Clinical Laboratory Immunology, Fifth Edition. Editors. Rose, Coneway de Macario, Folds, Lane, Nakamura.  Publisher: American Society for Microbiology. 1997. pp. 781-787

 4. Elbeik T, Feinberg MA. Isolation and quantitation of HIV.  In:  The AIDS Knowledge Base.  Little Brown Publishing, New York, 1994

Articles:

  1. Elbeik T.  The Viral Load Assay.  Statlanders Pharmacy News Letter.  Summer Edition, 1996.

  2. Elbeik T, Hahn H, Jenny-Avital E, McCutchan F, Myers R.  Genetic diversity of HIV. African Services Committee, New York, NY Edt. R Pearson, K Nichols. Proceedings of the Emory Conference Center Hotel, Atlanta, Georgia, April 12, 2000.